The economic burden of advanced liver disease among patients with hepatitis C virus: a large state Medicaid perspective

Joseph Menzin, Leigh Ann White, Christine Nichols, Baris Deniz, Joseph Menzin, Leigh Ann White, Christine Nichols, Baris Deniz

Abstract

Background: Chronic hepatitis C virus (HCV) may progress to advanced liver disease (ALD), including decompensated cirrhosis and/or hepatocellular carcinoma (HCC). ALD can lead to significant clinical and economic consequences, including liver transplantation. This study evaluated the health care costs associated with ALD among HCV infected patients in a Medicaid population.

Methods: Using Florida Medicaid claims data, cases were patients with at least 1 diagnosis of HCV or prescription therapy for HCV (ribavirin plus interferon, peginterferon, or interferon alfacon-1) prior to an incident ALD-related diagnosis ("index event") between 1999 and 2007. ALD-related conditions included decompensated cirrhosis, HCC, or liver transplant. A cohort of HCV patients without ALD (comparison group subjects) were matched 1-to-1 based on age, sex, and race. Baseline and follow-up were the 12 months prior to and following index, respectively; with both periods allowing for a maximum one month gap in eligibility. For both case and comparison patient cohorts, per-patient-per-eligible month (PPPM) costs were calculated as total Medicaid paid amount for each patient over their observed number of eligible months in follow-up, divided by the patient's total number of eligible months. A generalized linear model (GLM) was constructed controlling for age, race, Charlson score, alcoholic cirrhosis, and hepatitis B to explore all-cause PPPM costs between study groups. The final study group included 1,193 cases and matched comparison patients (mean age: 49 years; 45% female; 54% white, 23% black, 23% other).

Results: The majority of ALD-related diagnoses were for decompensated cirrhosis (92%), followed by HCC (6%) and liver transplant (2%). Cases had greater comorbidity (mean Charlson score: 3.1 vs. 2.3, P < 0.001). All-cause inpatient use up to 1-year following incident ALD diagnosis was significantly greater among cases with ALD (74% vs. 27%, P < 0.001). In the GLM, cases had 2.39 times greater total adjusted mean all-cause PPPM costs compared to the comparison group ($4,956 vs. $1,735 respectively; P < 0.001). Among cases, mean total unadjusted ALD-related costs were $1,356 PPPM, which were largely driven by inpatient costs ($1,272).

Conclusions: Our results suggest that among patients diagnosed with HCV, the incremental costs of developing ALD are substantial, with inpatient stays as the main driver of these increased costs.

Figures

Figure 1
Figure 1
Patient selection flowchart. Source: Florida Medicaid database: claims with dates of service between July 1, 1998 and June 30, 2008. 1 Hepatitis C Virus (HCV) was defined as acute, chronic, and other unspecified HCV 2 Advanced Liver Disease (ALD) was defined as decompensated cirrhosis, hepatocellular carcinoma, or liver transplant procedure/history.

References

    1. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(Suppl 1):74–81.
    1. McQuillan GM, Kruszon-Moran D, Denniston M, Hirsch R. Viral Hepatitis. National Center for Health Statistics, 2010; 2010. Available at: URL: . Accessed February 10, 11 A.D.
    1. Centers for Disease Control and Prevention (CDC) Hepatitis C Information for Health Professionals. Centers for Disease Control and Prevention (CDC); 2010. Available at: URL: . Accessed February 25, 2011.
    1. Armstrong EP, Charland SL. Burden of illness of hepatitis C from a managed care organization perspective. Curr Med Res Opin. 2004;20(5):671–679. doi: 10.1185/030079904125003485.
    1. Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol. 2011;45(2):e17–e24. doi: 10.1097/MCG.0b013e3181e12c09.
    1. Poret AW, Ozminkowski RJ, Goetzel R, Pew JE, Balent J. Cost burden of illness for hepatitis C patients with employer-sponsored health insurance. Dis Manag. 2002;5(2):95–107. doi: 10.1089/109350702320229195.
    1. Rosenberg DM, Cook SF, Lanza LL. Health care, treatment patterns and cost of services for patients infected with chronic hepatitis C virus in a large insured New England population. J Viral Hepat. 2000;7(5):361–367. doi: 10.1046/j.1365-2893.2000.00232.x.
    1. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 2003;9(4):331–338. doi: 10.1053/jlts.2003.50073.
    1. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterol. 2010;138(2):513–521. doi: 10.1053/j.gastro.2009.09.067.
    1. McHutchison JG, Bacon BR. Chronic hepatitis C: an age wave of disease burden. Am J Manag Care. 2005;11(10 Suppl):S286–S295.
    1. United States Census Bureau. Income, Poverty, and Health Insurance Coverage inthe United States: 2010. US Census; 2011. Available at: URL: . Accessed October 17, 2012.
    1. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90(10):1562–1569.
    1. El Khoury AC, Klimack WK, Wallace C, Razavi H. Economic burden of hepatitis C-associated diseases in the United States. J Viral Hepat. 2012;19(3):153–160. doi: 10.1111/j.1365-2893.2011.01563.x.
    1. Institute of Medicine. Hepatitis and Liver Cancer A National Strategy for Prevention and Control of Hepatitis B and C. IOM; 2010. January; Available at: URL: . Accessed October 30, 2012.
    1. Florida Agency for Health Care Administration. Florida Medicaid. AHCA; 2010. Available at: URL: . Accessed November 29, 2010.
    1. U.S. Census Bureau. Annual Estimates of the Resident Population for the United States, Regions, States, and Puerto Rico: April 1, 2000 to July 1, 2009. U S Census Bureau; 2010. Available at: URL: . Accessed February 10, 11 A.D.
    1. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83. doi: 10.1016/0021-9681(87)90171-8.
    1. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clinical Epidemiology. 1992;45(6):613–619. doi: 10.1016/0895-4356(92)90133-8.
    1. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CD administrative data: differing perspectives. J Clin Epidemiol. 1993;46(10):1075–79. doi: 10.1016/0895-4356(93)90103-8.
    1. McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm. 2011;17(7):531–546.
    1. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217–231. doi: 10.1016/j.jhep.2005.10.013.
    1. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;53(327):337.
    1. Holahan J, Miller DM, Rousseau D. Dual Eligibles: Medicaid Enrollment and Spending for Medicare Beneficiaries in 2005. Kaiser Family Foundation; 2009. Available at: URL: . Accessed March 28, 201.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe